EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Titrating Rituximab to Circulating B‐Cells Starting From an Ultra‐Low Dose for Moderate‐to‐Severe Pemphigus

Rui Wang, Sai Wang, Panpan Shang, Xixue Chen, Ruoyu Li, Mingyue Wang

Dermatologic Therapy · 2026-01 · 2026 (1)

DOI: 10.1155/dth/1828296 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Dermatologic Therapy, online erschienen am 29.06.2026. Verfasst von Rui Wang und 5 weiteren Autor:innen. Die Arbeit nennt 30 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Peking University First Hospital.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Rituximab has been proven effective at a dose of 2 g in moderate‐to‐severe pemphigus by depleting CD20 + B‐cell; however, studies have found that 100 mg RTX may suffice to fully suppress CD20 + B‐cell.

Objective

We aimed at investigating the efficacy, safety, and prognostic factors of titrating RTX to circulating B‐cells starting from 100 mg until the B‐cells depleted for moderate‐to‐severe pemphigus.

Methods

We performed a prospective, single‐arm study including moderate‐to‐severe pemphigus from August 2022 to June 2023; the follow‐up period was one year. Patients were treated with RTX at a first dose of 100 mg. If B‐cells were not depleted after 30 days, patients received a second infusion with 500 mg. If B‐cells were still not depleted 30 days later, patients received a third infusion with 1000 mg. Prednisone was administered at an initial dosage of 0.5 mg/kg/day for moderate and 1.0 mg/kg/day for severe pemphigus. The primary endpoint was the proportion of patients who achieved complete remission on minimal therapy (CROMT).

Results

A total of 50 patients were enrolled. Thirty‐one (62.0%) patients achieved B‐cell depletion with 100 mg RTX, and 18 (36.0%) patients needed a second dose of 500 mg, only one (2.0%) patient needed a third dose of 1000 mg. All patients achieved disease control. Thirty‐five (70%) patients achieved CROMT in a median time of 292.0 days. Nine (18%) patients relapsed; they all received only 100 mg RTX, and the mean time to relapse was 172.22 ± 67.15 days. No major adverse events occurred. Females (OR, 8.335; p = 0.003) and patients < 40 (OR, 15.669; p = 0.018) were more likely to achieve B‐cell depletion, and patients ≤ 37 (HR, 4.134; p = 0.038) were more likely to relapse.

Conclusions

Our personalized regimen could be an effective and safe treatment for pemphigus. A higher dose of RTX may be able to maintain a longer stable state of the disease. Being female and age less than 40 may be positive influencing factors for B‐cell depletion. Age less than or equal to 37 may be a negative prognostic factor for relapse. Trial Registration: Chinese Clinical Trial Registry: ChiCTR2200062766

Förderung

  • Peking University First Hospital

Zitieren

APA

Wang, R., Wang, S., Shang, P., Chen, X., Li, R., & Wang, M. (2026). Titrating Rituximab to Circulating B‐Cells Starting From an Ultra‐Low Dose for Moderate‐to‐Severe Pemphigus. Dermatologic Therapy, 2026(1). https://doi.org/10.1155/dth/1828296

Vancouver

Wang R, Wang S, Shang P, Chen X, Li R, Wang M. Titrating Rituximab to Circulating B‐Cells Starting From an Ultra‐Low Dose for Moderate‐to‐Severe Pemphigus. Dermatologic Therapy. 2026;2026(1). doi:10.1155/dth/1828296

BibTeX
@article{Wang2026,
  author = {Wang, Rui and Wang, Sai and Shang, Panpan and Chen, Xixue and Li, Ruoyu and Wang, Mingyue},
  title = {Titrating Rituximab to Circulating B‐Cells Starting From an Ultra‐Low Dose for Moderate‐to‐Severe Pemphigus},
  journal = {Dermatologic Therapy},
  year = {2026},
  volume = {2026},
  number = {1},
  doi = {10.1155/dth/1828296}
}
Kostenlos starten →